LimFlow recalled 33 units of its Vector model VT-US-23 on December 5, 2025, due to incorrect expiration dates. Patients and healthcare providers should stop using this device immediately. The recall affects distribution across 14 states and the District of Columbia.
Incorrect expiration date
Patients and healthcare providers should stop using this device immediately. Follow the recall instructions provided by the manufacturer. Contact LimFlow, Inc. or your healthcare provider for instructions. Notification method: Letter
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
The recalled product is the LimFlow Vector, model VT-US-23, with lot code 82321838. It was distributed nationwide in states including Alabama, California, New York, and Texas.
The recall stems from an incorrect expiration date, which may mislead users about the product's safety and effectiveness. Using an expired medical device can pose serious health risks.
No incidents or injuries related to this recall have been reported. The high hazard level indicates significant risks associated with usage.
Stop using the LimFlow Vector immediately. Contact LimFlow, Inc. or your healthcare provider for further instructions and follow the recall guidelines provided in the notification letter.
For assistance, contact LimFlow at [insert phone number] or visit their website at [insert website]. More details are available at the FDA recall link.
Get instant alerts for recalls that affect you. Free forever.
Taro Pharmaceuticals announced a market withdrawal of Diclofenac Sodium, Topical Gel, 3% on January 27, 2026. The withdrawal stems from out of specification viscosity results. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,057 bags of Acyclovir Sodium Injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers should cease use immediately and contact the manufacturer for guidance.
Fresenius Kabi Compounding recalled its vancomycin HCl injection on February 5, 2026, due to a lack of assurance of sterility. This Class II recall affects all lots distributed nationwide. Healthcare providers and consumers must stop using the product immediately.
Fresenius Kabi Compounding recalled 1,578 bags of vancomycin HCl injection on February 5, 2026. The company cited a lack of assurance of sterility as the reason for the recall. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,410 bags of ketamine HCl injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers and consumers must stop using this product immediately.
Fresenius Kabi Compounding recalled 10,548 bags of thiamine HCl injection on February 5, 2026. The recall follows a lack of assurance of sterility, posing a high health risk. Affected products include several lots expiring between February and May 2026.
Pro Numb Tattoo Numbing Spray was recalled on February 2, 2026 due to cGMP deviations. The product, containing 4% lidocaine, is distributed by Pro Numb Tattoo Numbing Spray LLC. Consumers should stop using it immediately and contact the company for further guidance.
Pro Numb Tattoo Numbing Spray was recalled due to cGMP deviations. The recall affects products distributed nationwide in the USA. Consumers should stop using the spray immediately and contact Pro Numb Tattoo Numbing Spray LLC for guidance.